ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
Key Highlights
- ➤ProKidney to host virtual KOL event October 27 at 10:30 AM ET
- ➤Katherine Tuttle to discuss rilparencel’s mechanism and potential advanced-CKD role
- ➤Anthony Conway to review rilparencel findings presented at ASN Kidney Week 2026
- ➤Management to provide a corporate update and live Q&A during event
- ➤Current cash expected to support operating plans into mid-2027
Expert Statements
Katherine Tuttle, Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington
“the remaining unmet need for patients with advanced Stage 3b/4 CKD and T2D despite recent therapeutic advances, and where rilparencel may fit within the evolving treatment paradigm”
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 27, 2026, at 10:30 AM ET. To register, click here.
The event will feature nephrology leader and researcher Katherine Tuttle, MD, who will join Company management to discuss new insights into rilparencel’s mechanism of action from research presented at the American Society of Nephrology (ASN) Kidney Week 2026, as well as the potential role of rilparencel in treating patients with advanced CKD and type 2 diabetes (T2D).
Get started
Create a free account to read the full story.